|
CORSO: Open issues in Oncology: New drugs for gastrointestinal, ovarian and lung cancer Roma, 20-21 May 2016 |
Direttore: Prof. Antonio Russo |
CREDITI ECM: |
SCARICA IL PDF... |
|
|
|
|
|
|
|
|
PROGRAMMA DEL CORSO (CLICCARE SULLE ICONE PER SCARICARE LE SLIDES) |
|
VENERDI, 20 MAGGIO |
10:00 |
Participant registration |
|
|
|
10:30 |
PRESENTATION OF THE MEETING |
Antonio Russo, President of the Conference, (Palermo) |
|
|
|
WELCOME TO THE CONFERENCE |
Clara Natoli, President of CINBO (Chieti) |
|
|
Moderatori: Clara Natoli (Chieti),
Pierosandro Tagliaferri (Catanzaro) |
|
|
|
Early tumor shrinkage and depth of response to
anti-EGFR in colorectal cancer: helpful surrogates
or meaningless endpoints? |
Marc Peeters (Anversa, BG) |
|
|
|
Perspectives from translational research
in gastrointestinal cancers |
Giampaolo Tortora (Padova) |
|
|
|
|
SESSION 1: Innovative strategies for gastrointestinal cancer |
Moderatori: Corrado Ficorella (L’Aquila)
Giuseppe Tonini (Roma) |
|
15:00 |
New anti-angiogenic agents in colorectal cancer |
Daniele Santini (Roma) |
|
|
15:20 |
Regorafenib in colorectal cancer: just a salvage treatment? |
Erika Martinelli (Napoli) |
|
|
15:40 |
Intensive chemotherapy for pancreatic cancer |
Nicola Silvestris (Bari) |
|
|
16:00 |
New chemotherapeutic agents for pancreatic cancer |
Davide Melisi (Verona) |
|
|
16:20 |
Liquid biopsy in gastrointestinal cancers |
Marta Castiglia (Palermo) |
|
|
16:40 |
Monoclonal antibodies in advanced gastric cancer |
Carlo Garufi (Pescara) |
|
|
|
|
17:30 |
Case reports and Discussion |
|
|
|
Moderatori: C. Garufi (Pescara), B. Vincenzi (Roma) |
|
|
Case report 1 |
Gemma Bruera (L’Aquila) |
|
|
|
Case report 2 |
Antonio Galvano (Palermo) |
|
|
|
SABATO, 21 MAGGIO |
|
Moderatori: Pierosandro Tagliaferri (Catanzaro) |
|
|
The angiogenesis in ovarian cancer:
bevacizumab and beyond |
Domenica Lorusso (Milano) |
|
|
|
SESSION 2: Innovative strategies for ovarian cancer |
Moderatori: Pierosandro Tagliaferri (Catanzaro),
Silverio Tomao (Roma) |
|
09:00 |
New chemotherapy to overcome platinum resistance |
Laura Cortesi (Modena) |
|
|
09:20 |
Next generation techniques for biomarker identifi cation |
Ettore Capoluongo (Roma) |
|
|
09:40 |
Preventive/predictive role of
susceptibility gene mutations |
Bernardo Bonanni (Milano) |
|
|
10:00 |
The clinical development of PARP inhibitors |
Enrico Ricevuto (L’Aquila) |
|
|
|
10:35 |
Case reports and Discussion |
|
|
|
Moderatori: Enrico Ricevuto (L’Aquila), Sergio Rizzo (Palermo) |
|
|
Case report 1 |
Lorena Incorvaia (Palermo) |
|
|
|
Case report 2 |
Valentina Calò (Palermo) |
|
|
|
|
Moderatori: Franco Silvestris |
|
|
The experience of Phase I trials in NSCLC:
what do we have to expect for next years? |
Christian Rolfo (Anversa, BG) |
|
|
|
SESSION 3 Innovation in 2nd line treatment for NSCLC |
Moderatori: Clara Natoli (Chieti)
Antonio Russo (Palermo) |
|
11:50 |
Multi-target agents and angiogenesis |
Roberto Bianco (Napoli) |
|
|
12:10 |
EGFR inhibitors for overcoming resistance |
Sergio Rizzo (Palermo) |
|
|
12:30 |
The right place for ALK inhibitors |
Mario Roselli (Roma) |
|
|
12:50 |
The new chance of immune checkpoint inhibitors |
Emilio Bria (Verona) |
|
|
|
13:20 |
Case reports and Discussion |
|
|
|
Moderatori: M. Roselli (Roma), Anna Russo (Palermo) |
|
|
Case report 1 |
Vito Barbieri (Catanzaro) |
|
|
|
Case report 2 |
Francesco Passiglia (Palermo) |
|
|